Home › Therapeutic areas › Oncology › Hepatocellular Carcinoma
Hepatocellular Carcinoma (9 companies)
Companies with an active program in Hepatocellular Carcinoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADAG | Adagene | Oncology | 1 | Phase 2 | $134M | 10 |
| CHRS | Coherus Oncology | Oncology | 1 | Approved | $119M | 4 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $137M | 15 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $503M | 10 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $17.0B | 23 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | $64.5M | 7 |
| REPL | Replimune Group | Oncology | 1 | Approved | $2.05B | 5 |
| TYRA | Tyra Biosciences | MetabolicOncology Rare | 1 | Phase 2 | $1.26B | 5 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $2.10B | 11 |
No companies match.